These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12816176)

  • 1. Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia.
    Kowalski J; Okopien B; Madej A; Zielinski M; Belowski D; Kalina Z; Herman ZS
    Int J Clin Pharmacol Ther; 2003 Jun; 41(6):241-7. PubMed ID: 12816176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
    Kowalski J; Okopień B; Madej A; Zieliński M; Belowski D; Kalina Z; Herman ZS
    Eur J Clin Pharmacol; 2003 Jul; 59(3):189-93. PubMed ID: 12756509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of sICAM-1, sVCAM-1 and MCP-1 in patients with hyperlipoproteinemia IIa and -IIb.
    Kowalski J; Okopien B; Madej A; Makowiecka K; Zielinski M; Kalina Z; Herman ZS
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):48-52. PubMed ID: 11270801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Levels of tumor necrosis factor alpha in serum of patients with hyperlipoproteinemia IIB before and after micronized fenofibrate therapy].
    Madej A; Okopień B; Kowalski J; Zieliński M; Wysocki J; Szyguła B; Kalina Z; Herman Z
    Pol Arch Med Wewn; 1998 Apr; 99(4):308-13. PubMed ID: 9760818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocyte suppressing action of fenofibrate.
    Okopień B; Kowalski J; Krysiak R; Łabuzek K; Stachura-Kułach A; Kułach A; Zieliński M; Herman ZS
    Pharmacol Rep; 2005; 57(3):367-72. PubMed ID: 15985720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb.
    Madej A; Okopien B; Kowalski J; Zielinski M; Wysocki J; Szygula B; Kalina Z; Herman ZS
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):345-9. PubMed ID: 9660044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances.
    Krysiak R; Gdula-Dymek A; Okopien B
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):198-202. PubMed ID: 22935083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extralipid effects of micronized fenofibrate in dyslipidemic patients.
    Okopień B; Haberka M; Madej A; Belowski D; Labuzek K; Krysiak R; Zieliński M; Basiak M; Herman ZS
    Pharmacol Rep; 2006; 58(5):729-35. PubMed ID: 17085865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
    Okopien B; Cwalina L; Lebek M; Kowalski J; Zielinski M; Wisniewska-Wanat M; Kalina Z; Herman ZS
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia.
    Raslová K; Dubovská D; Mongiellová V; Trnovec T
    Eur J Clin Pharmacol; 1997; 52(2):101-6. PubMed ID: 9174678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension.
    Madej A; Okopień B; Kowalski J; Haberka M; Herman ZS
    Pharmacol Rep; 2005; 57(6):878-81. PubMed ID: 16382212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fibrates in clinical practice: focus on micronised fenofibrate.
    Shepherd J
    Atherosclerosis; 1994 Oct; 110 Suppl():S55-63. PubMed ID: 7857386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Semra YK; Crook MA
    QJM; 1998 Apr; 91(4):291-4. PubMed ID: 9666952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia].
    Ren JY; Chen H; Luo Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb; 33(2):122-6. PubMed ID: 15924805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1.
    Parissis JT; Korovesis S; Giazitzoglou E; Kalivas P; Katritsis D
    Int J Cardiol; 2002 Apr; 83(1):13-21. PubMed ID: 11959378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Cheung J; Crook MA
    QJM; 1997 Oct; 90(10):631-4. PubMed ID: 9415344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment.
    Ceriello A; Quagliaro L; Piconi L; Assaloni R; Da Ros R; Maier A; Esposito K; Giugliano D
    Diabetes; 2004 Mar; 53(3):701-10. PubMed ID: 14988255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
    Krysiak R; Gdula-Dymek A; Marek B; Okopień B
    Endokrynol Pol; 2015; 66(3):224-30. PubMed ID: 26136131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia.
    Kirchgässler KU; Schiffner-Rohe J; Stahlheber U
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):237-46. PubMed ID: 10173126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.